418 
an arrangement with the Institute of Medicine (or, if the 
Institute declines to enter into such an arrangement, an-
other appropriate entity)— 
(1) to conduct a study with respect to mental 
and behavioral health disparities in racial and ethnic 
minority groups (as defined in section 1707(g) of 
the Public Health Service Act (42 U.S.C. 300u– 
6(g)); and 
(2) to submit to the Congress a report on the 
results of such study, including— 
(A) a compilation of information on the dy-
namics of mental disorders in such racial and 
ethnic minority groups; and 
(B) a compilation of information on the 
impact of exposure to community violence, ad-
verse childhood experiences, and other psycho-
logical traumas on mental disorders in such ra-
cial and minority groups. 
SEC. 605. HEALTH PROFESSIONS COMPETENCIES TO AD-
DRESS RACIAL AND ETHNIC MINORITY MEN-
TAL HEALTH DISPARITIES. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Administrator of the 
Substance Abuse and Mental Health Services Administra-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00418
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
419 
tion, shall award grants to qualified national organizations 
for the purposes of— 
(1) developing, and disseminating to health pro-
fessional educational programs curricula or core 
competencies addressing mental health disparities 
among racial and ethnic minority groups for use in 
the training of students in the professions of social 
work, psychology, psychiatry, marriage and family 
therapy, peer wellness specialist, mental health coun-
seling, and substance abuse counseling; and 
(2) certifying community health workers and 
peer wellness specialists with respect to such cur-
ricula and core competencies and integrating and ex-
panding the use of such workers and specialists into 
health care to address mental health disparities 
among racial and ethnic minority groups. 
(b) CURRICULA; CORE COMPETENCIES.—Organiza-
tions receiving funds under subsection (a) may use the 
funds to engage in the following activities related to the 
development and dissemination of curricula or core com-
petencies described in subsection (a)(1): 
(1) Formation of committees or working groups 
comprised of experts from accredited health profes-
sions schools to identify core competencies relating 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00419
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
420 
to mental health disparities among racial and ethnic 
minority groups. 
(2) Planning of workshops in national fora to 
allow for public input into the educational needs as-
sociated with mental health disparities among racial 
and ethnic minority groups. 
(3) Dissemination and promotion of the use of 
curricula or core competencies in undergraduate and 
graduate health professions training programs na-
tionwide. 
(c) DEFINITIONS.—In this section: 
(1) The term ‘‘qualified national organization’’ 
means a national organization that focuses on the 
education of students in programs of social work, 
psychology, psychiatry, and marriage and family 
therapy. 
(2) The term ‘‘racial and ethnic minority 
group’’ has the meaning given to such term in sec-
tion 1707(g) of the Public Health Service Act (42 
U.S.C. 300u–6(g)). 
(d) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
such sums as may be necessary for each of fiscal years 
2017 through 2021. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00420
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
421 
TITLE VII—ADDRESSING HIGH 
IMPACT MINORITY DISEASES 
Subtitle A—Cancer 
SEC. 701. LUNG CANCER MORTALITY REDUCTION. 
(a) SHORT TITLE.—This section may be cited as the 
‘‘Lung Cancer Mortality Reduction Act of 2016’’. 
(b) FINDINGS.—Congress makes the following find-
ings: 
(1) Lung cancer is the leading cause of cancer 
death for both men and women, accounting for 28 
percent of all cancer deaths. 
(2) Lung cancer kills more people annually 
than breast cancer, prostate cancer, colon cancer, 
liver cancer, melanoma, and kidney cancer combined. 
(3) Since the National Cancer Act of 1971 
(Public Law 92–218; 85 Stat. 778), coordinated and 
comprehensive research has raised the 5-year sur-
vival rates for breast cancer to 88 percent, for pros-
tate cancer to 99 percent, and for colon cancer to 
64 percent. 
(4) However, the 5-year survival rate for lung 
cancer is still only 15 percent and a similar coordi-
nated and comprehensive research effort is required 
to achieve increases in lung cancer survivability 
rates. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00421
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
422 
(5) Sixty percent of lung cancer cases are now 
diagnosed nonsmokers or former smokers. 
(6) Two-thirds of nonsmokers diagnosed with 
lung cancer are women. 
(7) Certain minority populations, such as Afri-
can-American males, have disproportionately high 
rates of lung cancer incidence and mortality, not-
withstanding their similar smoking rate. 
(8) Members of the baby boomer generation are 
entering their sixties, the most common age at which 
people develop lung cancer. 
(9) Tobacco addiction and exposure to other 
lung cancer carcinogens such as Agent Orange and 
other herbicides and battlefield emissions are serious 
problems among military personnel and war vet-
erans. 
(10) Significant and rapid improvements in 
lung cancer mortality can be expected through great-
er use and access to lung cancer screening tests for 
at-risk individuals. 
(11) Recent research has shown that screening 
with low-dose computed tomography (CT) scan im-
proved lung cancer death mortality by 20 percent for 
those with a high risk of lung cancer through early 
detection. The Centers for Medicare & Medicaid 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00422
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
423 
Services supports annual lung cancer screening for 
high-risk patients with low-dose computed tomog-
raphy. 
(12) Additional strategies are necessary to fur-
ther enhance the existing tests and therapies avail-
able to diagnose and treat lung cancer in the future. 
(13) The August 2001 Report of the Lung 
Cancer Progress Review Group of the National Can-
cer Institute stated that funding for lung cancer re-
search was ‘‘far below the levels characterized for 
other common malignancies and far out of propor-
tion to its massive health impact’’. 
(14) The Report of the Lung Cancer Progress 
Review Group identified as its ‘‘highest priority’’ the 
creation of integrated, multidisciplinary, multi-insti-
tutional research consortia organized around the 
problem of lung cancer rather than around specific 
research disciplines. 
(15) The United States must enhance its re-
sponse to the issues raised in the Report of the 
Lung Cancer Progress Review Group, and this can 
be accomplished through the establishment of a co-
ordinated effort designed to reduce the lung cancer 
mortality rate by 50 percent by 2020 and targeted 
funding to support this coordinated effort. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00423
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
424 
(c) SENSE OF CONGRESS CONCERNING INVESTMENT 
IN LUNG CANCER RESEARCH.—It is the sense of the Con-
gress that— 
(1) lung cancer mortality reduction should be 
made a national public health priority; and 
(2) a comprehensive mortality reduction pro-
gram coordinated by the Secretary of Health and 
Human Services is justified and necessary to ade-
quately address and reduce lung cancer mortality. 
(d) LUNG CANCER MORTALITY REDUCTION PRO-
GRAM.— 
(1) IN GENERAL.—Subpart 1 of part C of title 
IV of the Public Health Service Act (42 U.S.C. 285 
et seq.) is amended by adding at the end the fol-
lowing: 
‘‘SEC. 417H. LUNG CANCER MORTALITY REDUCTION PRO-
GRAM. 
‘‘(a) IN GENERAL.—Not later than 6 months after 
the date of the enactment of this section, the Secretary, 
in consultation with the Secretary of Defense, the Sec-
retary of Veterans Affairs, the Director of the National 
Institutes of Health, the Director of the Centers for Dis-
ease Control and Prevention, the Commissioner of Food 
and Drugs, the Administrator of the Centers for Medicare 
& Medicaid Services, the Director of the National Institute 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00424
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
425 
on Minority Health and Health Disparities, and other 
members of the Lung Cancer Advisory Board established 
under section 701 of the Health Equity and Accountability 
Act of 2016, shall implement a comprehensive program, 
to be known as the Lung Cancer Mortality Reduction Pro-
gram, to achieve a reduction of at least 25 percent in the 
mortality rate of lung cancer by 2020. 
‘‘(b) REQUIREMENTS.—The Program shall include at 
least the following: 
‘‘(1) With respect to the National Institutes of 
Health— 
‘‘(A) a strategic review and prioritization 
by the National Cancer Institute of research 
grants to achieve the goal of the Lung Cancer 
Mortality Reduction Program in reducing lung 
cancer mortality; 
‘‘(B) the provision of funds to enable the 
Airway Biology and Disease Branch of the Na-
tional Heart, Lung, and Blood Institute to ex-
pand its research programs to include pre-
dispositions to lung cancer, the interrelationship 
between lung cancer and other pulmonary and 
cardiac disease, and the diagnosis and treat-
ment of these interrelationships; 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00425
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
426 
‘‘(C) the provision of funds to enable the 
National Institute of Biomedical Imaging and 
Bioengineering to expedite the development of 
computer-assisted diagnostic, surgical, treat-
ment, and drug-testing innovations to reduce 
lung cancer mortality, such as through expan-
sion of the Institute’s Quantum Grant Program 
and Image-Guided Interventions programs; and 
‘‘(D) the provision of funds to enable the 
National Institute of Environmental Health 
Sciences to implement research programs rel-
ative to the lung cancer incidence. 
‘‘(2) With respect to the Food and Drug Ad-
ministration— 
‘‘(A) activities under section 530 of the 
Federal Food, Drug, and Cosmetic Act; and 
‘‘(B) activities under section 561 of the 
Federal Food, Drug, and Cosmetic Act to ex-
pand access to investigational drugs and devices 
for the diagnosis, monitoring, or treatment of 
lung cancer. 
‘‘(3) With respect to the Centers for Disease 
Control and Prevention, the establishment of an 
early disease research and management program 
under section 1511. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00426
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
427 
‘‘(4) With respect to the Agency for Healthcare 
Research and Quality, the conduct of a biannual re-
view of lung cancer screening, diagnostic, and treat-
ment protocols, and the issuance of updated guide-
lines. 
‘‘(5) The promotion (including education) of 
lung cancer screening within minority and rural pop-
ulations and the study of the effectiveness of efforts 
to increase such screening. 
‘‘(6) The cooperation and coordination of all 
minority and health disparity programs within the 
Department of Health and Human Services to en-
sure that all aspects of the Lung Cancer Mortality 
Reduction Program under this section adequately 
address the burden of lung cancer on minority and 
rural populations. 
‘‘(7) The cooperation and coordination of all to-
bacco control and cessation programs within agen-
cies of the Department of Health and Human Serv-
ices to achieve the goals of the Lung Cancer Mor-
tality Reduction Program under this section with 
particular emphasis on the coordination of drug and 
other cessation treatments with early detection pro-
tocols.’’. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00427
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
428 
(2) FEDERAL
FOOD, DRUG, AND
COSMETIC 
ACT.—Subchapter B of chapter V of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 360aaa et 
seq.) is amended by adding at the end the following: 
‘‘DRUGS RELATING TO LUNG CANCER 
‘‘SEC. 530. (a) IN GENERAL.—The provisions of this 
subchapter shall apply to a drug described in subsection 
(b) to the same extent and in the same manner as such 
provisions apply to a drug for a rare disease or condition. 
‘‘(b) QUALIFIED DRUGS.—A drug described in this 
subsection is— 
‘‘(1) a chemoprevention drug for precancerous 
conditions of the lung; 
‘‘(2) a drug for targeted therapeutic treat-
ments, including any vaccine, for lung cancer; and 
‘‘(3) a drug to curtail or prevent nicotine addic-
tion. 
‘‘(c) BOARD.—The Board established under the 
Health Equity and Accountability Act of 2016 shall mon-
itor the program implemented under this section.’’. 
(3) ACCESS TO UNAPPROVED THERAPIES.—Sec-
tion 561(e) of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360bbb(e)) is amended by in-
serting before the period the following: ‘‘and shall 
include expanding access to drugs under section 
530, with substantial consideration being given to 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00428
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
429 
whether the totality of information available to the 
Secretary regarding the safety and effectiveness of 
an investigational drug, as compared to the risk of 
morbidity and death from the disease, indicates that 
a patient may obtain more benefit than risk if treat-
ed with the drug’’. 
(4) CDC.—Title XV of the Public Health Serv-
ice Act (42 U.S.C. 300k et seq.) is amended by add-
ing at the end the following: 
‘‘SEC. 1511. EARLY DISEASE RESEARCH AND MANAGEMENT 
PROGRAM. 
‘‘The Secretary shall establish and implement an 
early disease research and management program targeted 
at the high incidence and mortality rates of lung cancer 
among minority and low-income populations.’’. 
(e) DEPARTMENT OF DEFENSE AND THE DEPART-
MENT OF VETERANS AFFAIRS.—The Secretary of Defense 
and the Secretary of Veterans Affairs shall coordinate 
with the Secretary of Health and Human Services— 
(1) in the development of the Lung Cancer 
Mortality Reduction Program under section 417H; 
(2) in the implementation within the Depart-
ment of Defense and the Department of Veterans 
Affairs of an early detection and disease manage-
ment research program for military personnel and 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00429
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
430 
veterans whose smoking history and exposure to car-
cinogens during active duty service has increased 
their risk for lung cancer; and 
(3) in the implementation of coordinated care 
programs for military personnel and veterans diag-
nosed with lung cancer. 
(f) LUNG CANCER ADVISORY BOARD.— 
(1) IN GENERAL.—The Secretary of Health and 
Human Services shall convene a Lung Cancer Advi-
sory Board (referred to in this section as the 
‘‘Board’’)— 
(A) to monitor the programs established 
under this section (and the amendments made 
by this section); and 
(B) to provide annual reports to the Con-
gress concerning benchmarks, expenditures, 
lung cancer statistics, and the public health im-
pact of such programs. 
(2) COMPOSITION.—The Board shall be com-
posed of— 
(A) the Secretary of Health and Human 
Services; 
(B) the Secretary of Defense; 
(C) the Secretary of Veterans Affairs; and 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00430
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
431 
(D) two representatives each from the 
fields of clinical medicine focused on lung can-
cer, lung cancer research, imaging, drug devel-
opment, and lung cancer advocacy, to be ap-
pointed by the Secretary of Health and Human 
Services. 
(g) AUTHORIZATION OF APPROPRIATIONS.— 
(1) IN
GENERAL.—To carry out this section 
(and the amendments made by this section), there 
are authorized to be appropriated such sums as may 
be necessary for each of fiscal years 2017 through 
2021. 
(2) LUNG CANCER MORTALITY REDUCTION PRO-
GRAM.—Of the amounts authorized to be appro-
priated by subsection (a), there are authorized to be 
appropriated— 
(A) $25,000,000 for fiscal year 2017, and 
such sums as may be necessary for each of fis-
cal years 2018 through 2021, for the activities 
described in section 417H(b)(1)(B) of the Pub-
lic Health Service Act, as added by subsection 
(d)(1); 
(B) $25,000,000 for fiscal year 2017, and 
such sums as may be necessary for each of fis-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00431
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
432 
cal years 2018 through 2021, for the activities 
described in section 417H(b)(1)(C) of such Act; 
(C) $10,000,000 for fiscal year 2017, and 
such sums as may be necessary for each of fis-
cal years 2018 through 2021, for the activities 
described in section 417H(b)(1)(D) of such Act; 
and 
(D) $15,000,000 for fiscal year 2017, and 
such sums as may be necessary for each of fis-
cal years 2018 through 2021, for the activities 
described in section 417H(b)(3) of such Act. 
SEC. 702. EXPANDING PROSTATE CANCER RESEARCH, OUT-
REACH, SCREENING, TESTING, ACCESS, AND 
TREATMENT EFFECTIVENESS. 
(a) SHORT TITLE.—This section may be cited as the 
‘‘Prostate Research, Outreach, Screening, Testing, Access, 
and Treatment Effectiveness Act of 2016’’ or the ‘‘PROS-
TATE Act’’. 
(b) FINDINGS.—Congress makes the following find-
ings: 
(1) Prostate cancer is the second leading cause 
of cancer death among men. 
(2) In 2010, more than 217,730 new patients 
were diagnosed with prostate cancer and more than 
32,000 men died from this disease. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00432
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
433 
(3) Roughly 2,000,000 Americans are living 
with a diagnosis of prostate cancer and its con-
sequences. 
(4) While prostate cancer generally affects older 
individuals, younger men are also at risk for the dis-
ease, and when prostate cancer appears in early 
middle age it frequently takes on a more aggressive 
form. 
(5) There are significant racial and ethnic dis-
parities that demand attention, namely African- 
Americans have prostate cancer mortality rates that 
are more than double those in the White population. 
(6) Underserved rural populations have higher 
rates of mortality compared to their urban counter-
parts, and innovative and cost-efficient methods to 
improve rural access to high quality care should take 
advantage of advances in telehealth to diagnose and 
treat prostate cancer when appropriate. 
(7) Certain veterans populations may have 
nearly twice the incidence of prostate cancer as the 
general population of the United States. 
(8) Urologists may constitute the specialists 
who diagnose and treat the vast majority of prostate 
cancer patients. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00433
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
434 
(9) Although much basic and translational re-
search has been completed and much is currently 
known, there are still many unanswered questions. 
For example, it is not fully understood how much of 
known disparities are attributable to disease eti-
ology, access to care, or education and awareness in 
the community. 
(10) Causes of prostate cancer are not known. 
There is not good information regarding how to dif-
ferentiate accurately, early on, between aggressive 
and indolent forms of the disease. As a result, there 
is significant overtreatment in prostate cancer. 
There are no treatments that can durably arrest 
growth or cure prostate cancer once it has metasta-
sized. 
(11) A significant proportion (roughly 23 to 54 
percent) of cases may be clinically indolent and 
‘‘overdiagnosed’’, resulting in significant overtreat-
ment. More accurate tests will allow men and their 
families to face less physical, psychological, financial, 
and emotional trauma and billions of dollars could 
be saved in private and public health care systems 
in an area that has been identified by the Medicare 
Program as one of eight high-volume, high-cost 
areas in the Resource Utilization Report Program 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00434
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
435 
authorized by Congress under the Medicare Im-
provements for Patients and Providers Act of 2008. 
(12) Prostate cancer research and health care 
programs across Federal agencies should be coordi-
nated to improve accountability and actively encour-
age the translation of research into practice, to iden-
tify and implement best practices, in order to foster 
an integrated and consistent focus on effective pre-
vention, diagnosis, and treatment of this disease. 
(c) PROSTATE CANCER COORDINATION AND EDU-
CATION.— 
(1) INTERAGENCY PROSTATE CANCER COORDI-
NATION AND EDUCATION TASK FORCE.—Not later 
than 180 days after the date of the enactment of 
this section, the Secretary of Veterans Affairs, in co-
operation with the Secretary of Defense and the Sec-
retary of Health and Human Services, shall estab-
lish an Interagency Prostate Cancer Coordination 
and Education Task Force (in this section referred 
to as the ‘‘Prostate Cancer Task Force’’). 
(2) DUTIES.—The Prostate Cancer Task Force 
shall— 
(A) develop a summary of advances in 
prostate cancer research supported or con-
ducted by Federal agencies relevant to the diag-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00435
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
436 
nosis, prevention, and treatment of prostate 
cancer, including psychosocial impairments re-
lated to prostate cancer treatment, and compile 
a list of best practices that warrant broader 
adoption in health care programs; 
(B) consider establishing, and advocating 
for, a guidance to enable physicians to allow 
screening of men who are over age 74, on a 
case-by-case basis, taking into account quality 
of life and family history of prostate cancer; 
(C) share and coordinate information on 
Federal research and health care program ac-
tivities, including activities related to— 
(i) determining how to improve re-
search and health care programs, including 
psychosocial impairments related to pros-
tate cancer treatment; 
(ii) identifying any gaps in the overall 
research inventory and in health care pro-
grams; 
(iii) identifying opportunities to pro-
mote translation of research into practice; 
and 
(iv) maximizing the effects of Federal 
efforts by identifying opportunities for col-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00436
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
437 
laboration and leveraging of resources in 
research and health care programs that 
serve those susceptible to or diagnosed 
with prostate cancer; 
(D) develop a comprehensive interagency 
strategy and advise relevant Federal agencies in 
the solicitation of proposals for collaborative, 
multidisciplinary research and health care pro-
grams, including proposals to evaluate factors 
that may be related to the etiology of prostate 
cancer, that would— 
(i) result in innovative approaches to 
study emerging scientific opportunities or 
eliminate knowledge gaps in research to 
improve the prostate cancer research port-
folio of the Federal Government; 
(ii) outline key research questions, 
methodologies, and knowledge gaps; and 
(iii) ensure consistent action, as out-
lined by section 402(b) of the Public 
Health Service Act; 
(E) develop a coordinated message related 
to screening and treatment for prostate cancer 
to be reflected in educational and beneficiary 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00437
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
438 
materials for Federal health programs as such 
documents are updated; and 
(F) not later than 2 years after the date 
of the establishment of the Prostate Cancer 
Task Force, submit to the Expert Advisory 
Panel to be reviewed and returned within 30 
days, and then within 90 days submitted to 
Congress recommendations— 
(i) regarding any appropriate changes 
to research and health care programs, in-
cluding recommendations to improve the 
research portfolio of the Department of 
Veterans Affairs, Department of Defense, 
National Institutes of Health, and other 
Federal agencies to ensure that scientif-
ically based strategic planning is imple-
mented in support of research and health 
care program priorities; 
(ii) designed to ensure that the re-
search and health care programs and ac-
tivities of the Department of Veterans Af-
fairs, the Department of Defense, the De-
partment of Health and Human Services, 
and other Federal agencies are free of un-
necessary duplication; 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00438
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
439 
(iii) regarding public participation in 
decisions relating to prostate cancer re-
search and health care programs to in-
crease the involvement of patient advo-
cates, community organizations, and med-
ical associations representing a broad geo-
graphical area; 
(iv) on how to best disseminate infor-
mation on prostate cancer research and 
progress achieved by health care programs; 
(v) about how to expand partnerships 
between public entities, including Federal 
agencies, and private entities to encourage 
collaborative, cross-cutting research and 
health care delivery; 
(vi) assessing any cost savings and ef-
ficiencies realized through the efforts iden-
tified and supported in this section and 
recommending expansion of those efforts 
that have proved most promising while also 
ensuring against any conflicts in directives 
from other congressional or statutory man-
dates or enabling statutes; 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00439
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
440 
(vii) identifying key priority action 
items from among the recommendations; 
and 
(viii) with respect to the level of fund-
ing needed by each agency to implement 
the recommendations contained in the re-
port. 
(3) MEMBERS OF THE PROSTATE CANCER TASK 
FORCE.—The Prostate Cancer Task Force described 
in subsection (a) shall be composed of representa-
tives from such Federal agencies, as each Secretary 
determines necessary, to coordinate a uniform mes-
sage relating to prostate cancer screening and treat-
ment where appropriate, including representatives of 
the following: 
(A) The Department of Veterans Affairs, 
including representatives of each relevant pro-
gram areas of the Department of Veterans Af-
fairs. 
(B) The Prostate Cancer Research Pro-
gram of the Congressionally Directed Medical 
Research Program of the Department of De-
fense. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00440
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
441 
(C) The Department of Health and 
Human Services, including at a minimum rep-
resentatives of the following: 
(i) The National Institutes of Health. 
(ii) National research institutes and 
centers, including the National Cancer In-
stitute, the National Institute of Allergy 
and Infectious Diseases, and the Office of 
Minority Health. 
(iii) The Centers for Medicare & Med-
icaid Services. 
(iv) The Food and Drug Administra-
tion. 
(v) The Centers for Disease Control 
and Prevention. 
(vi) The Agency for Healthcare Re-
search and Quality. 
(vii) The Health Resources and Serv-
ices Administration. 
(4) APPOINTING EXPERT ADVISORY PANELS.— 
The Prostate Cancer Task Force shall appoint ex-
pert advisory panels, as determined appropriate, to 
provide input and concurrence from individuals and 
organizations from the medical, prostate cancer pa-
tient and advocate, research, and delivery commu-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00441
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
442 
nities with expertise in prostate cancer diagnosis, 
treatment, and research, including practicing urolo-
gists, primary care providers, and others and indi-
viduals with expertise in education and outreach to 
underserved populations affected by prostate cancer. 
(5) MEETINGS.—The Prostate Cancer Task 
Force shall convene not less than twice a year, or 
more frequently as the Secretary determines to be 
appropriate. 
(6) SUBMISSION
OF
RECOMMENDATIONS
TO 
CONGRESS.—The Secretary of Veterans Affairs shall 
submit to Congress any recommendations submitted 
to the Secretary under paragraph (2)(E). 
(7) FEDERAL ADVISORY COMMITTEE ACT.— 
(A) IN GENERAL.—Except as provided in 
subparagraph (B), the Federal Advisory Com-
mittee Act (5 U.S.C. App.) shall apply to the 
Prostate Cancer Task Force. 
(B) EXCEPTION.—Section 14(a)(2)(B) of 
such Act (relating to the termination of advi-
sory committees) shall not apply to the Prostate 
Cancer Task Force. 
(8) SUNSET DATE.—The Prostate Cancer Task 
Force shall terminate at the end of fiscal year 2021. 
(d) PROSTATE CANCER RESEARCH.— 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00442
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
443 
(1) RESEARCH COORDINATION.—The Secretary 
of Veterans Affairs, in coordination with the Secre-
taries of Defense and of Health and Human Serv-
ices, shall establish and carry out a program to co-
ordinate and intensify prostate cancer research as 
needed. Specifically, such research program shall— 
(A) develop advances in diagnostic and 
prognostic methods and tests, including bio-
markers and an improved prostate cancer 
screening blood test, including improvements or 
alternatives to the prostate specific antigen test 
and additional tests to distinguish indolent from 
aggressive disease; 
(B) better understand the etiology of the 
disease (including an analysis of lifestyle factors 
proven to be involved in higher rates of prostate 
cancer, such as obesity and diet, and in dif-
ferent ethnic, racial, and socioeconomic groups, 
such as the African-American, Latino or His-
panic, and American Indian populations and 
men with a family history of prostate cancer) to 
improve prevention efforts; 
(C) expand basic research into prostate 
cancer, including studies of fundamental molec-
ular and cellular mechanisms; 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00443
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
444 
(D) identify and provide clinical testing of 
novel agents for the prevention and treatment 
of prostate cancer; 
(E) establish clinical registries for prostate 
cancer; 
(F) use the National Institute of Bio-
medical Imaging and Bioengineering and the 
National Cancer Institute for assessment of ap-
propriate imaging modalities; and 
(G) address such other matters relating to 
prostate cancer research as may be identified by 
the Federal agencies participating in the pro-
gram under this section. 
(2) PROSTATE
CANCER
ADVISORY
BOARD.— 
There is established in the Office of the Chief Sci-
entist of the Food and Drug Administration a Pros-
tate Cancer Scientific Advisory Board. Such board 
shall be responsible for accelerating real-time shar-
ing of the latest research data and accelerating 
movement of new medicines to patients. 
(3) UNDERSERVED
MINORITY
GRANT
PRO-
GRAM.—In carrying out such program, the Secretary 
shall— 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00444
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
445 
(A) award grants to eligible entities to 
carry out components of the research outlined 
in paragraph (1); 
(B) integrate and build upon existing 
knowledge gained from comparative effective-
ness research; and 
(C) recognize and address— 
(i) the racial and ethnic disparities in 
the incidence and mortality rates of pros-
tate cancer and men with a family history 
of prostate cancer; 
(ii) any barriers in access to care and 
participation in clinical trials that are spe-
cific to racial, ethnic, and other under-
served minorities and men with a family 
history of prostate cancer; 
(iii) needed outreach and educational 
efforts to raise awareness in these commu-
nities; and 
(iv) appropriate access and utilization 
of imaging modalities. 
(e) TELEHEALTH
AND
RURAL
ACCESS
PILOT 
PROJECT.— 
(1) IN GENERAL.—The Secretary of Veterans 
Affairs, the Secretary of Defense, and the Secretary 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00445
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
446 
of Health and Human Services (in this section re-
ferred to as the ‘‘Secretaries’’) shall establish 4-year 
telehealth pilot projects for the purpose of analyzing 
the clinical outcomes and cost effectiveness associ-
ated with telehealth services in a variety of geo-
graphic areas that contain high proportions of medi-
cally underserved populations, including African- 
Americans, Latino or Hispanic, American Indians/ 
Alaska Natives, and those in rural areas. Such 
projects shall promote efficient use of specialist care 
through better coordination of primary care and 
physician extender teams in underserved areas and 
more effectively employ tumor boards to better coun-
sel patients. 
(2) ELIGIBLE ENTITIES.— 
(A) IN
GENERAL.—The Secretaries shall 
select eligible entities to participate in the pilot 
projects under this section. 
(B) PRIORITY.—In selecting eligible enti-
ties to participate in the pilot projects under 
this section, the Secretaries shall give priority 
to such entities located in medically under-
served areas, particularly those that include Af-
rican-Americans, Latinos and Hispanics, and 
facilities of the Indian Health Service, including 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00446
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
447 
Indian Health Service operated facilities, trib-
ally operated facilities, and Urban Indian Clin-
ics, and those in rural areas. 
(3) 
EVALUATION.—The 
Secretaries 
shall, 
through the pilot projects, evaluate— 
(A) the effective and economic delivery of 
care in diagnosing and treating prostate cancer 
with the use of telehealth services in medically 
underserved and tribal areas including collabo-
rative uses of health professionals and integra-
tion of the range of telehealth and other tech-
nologies; 
(B) the effectiveness of improving the ca-
pacity of nonmedical providers and nonspecial-
ized medical providers to provide health services 
for prostate cancer in medically underserved 
and tribal areas, including the exploration of in-
novative medical home models with collabora-
tion between urologists, other relevant medical 
specialists, including oncologists, radiologists, 
and primary care teams and coordination of 
care through the efficient use of primary care 
teams and physician extenders; and 
(C) the effectiveness of using telehealth 
services to provide prostate cancer treatment in 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00447
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
448 
medically underserved areas, including the use 
of tumor boards to facilitate better patient 
counseling. 
(4) REPORT.—Not later than 12 months after 
the completion of the pilot projects under this sub-
section, the Secretaries shall submit to Congress a 
report describing the outcomes of such pilot projects, 
including any cost savings and efficiencies realized, 
and providing recommendations, if any, for expand-
ing the use of telehealth services. 
(f) EDUCATION AND AWARENESS.— 
(1) IN GENERAL.—The Secretary of Veterans 
Affairs shall develop a national education campaign 
for prostate cancer. Such campaign shall involve the 
use of written educational materials and public serv-
ice announcements consistent with the findings of 
the Prostate Cancer Task Force under subsection 
(c), that are intended to encourage men to seek 
prostate cancer screening when appropriate. 
(2) RACIAL DISPARITIES AND THE POPULATION 
OF
MEN
WITH
A
FAMILY
HISTORY
OF
PROSTATE 
CANCER.—In developing the national campaign 
under paragraph (1), the Secretary shall ensure that 
such educational materials and public service an-
nouncements are more readily available in commu-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00448
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
449 
nities experiencing racial disparities in the incidence 
and mortality rates of prostate cancer and by men 
of any race classification with a family history of 
prostate cancer. 
(3) GRANTS.—In carrying out the national 
campaign under this section, the Secretary shall 
award grants to nonprofit private entities to enable 
such entities to test alternative outreach and edu-
cation strategies. 
(g) AUTHORIZATION OF APPROPRIATIONS.— 
(1) IN GENERAL.—There is authorized to be 
appropriated to carry out this section for the period 
of fiscal years 2017 through 2021 an amount equal 
to the savings described in paragraph (2). 
(2) 
CORRESPONDING
REDUCTION.—The 
amount authorized to be appropriated by provisions 
of law other than this section for the period of fiscal 
years 2017 through 2021 for Federal research and 
health care program activities related to prostate 
cancer is reduced by the amount of Federal savings 
projected to be achieved over such period by imple-
mentation of subsection (c)(2)(C) of this section. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00449
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
450 
SEC. 703. IMPROVED MEDICAID COVERAGE FOR CERTAIN 
BREAST AND CERVICAL CANCER PATIENTS 
IN THE TERRITORIES. 
(a) ELIMINATION OF FUNDING LIMITATIONS.— 
(1) IN GENERAL.—Section 1108(g)(4) of the 
Social Security Act (42 U.S.C. 1308(g)(4)) is 
amended by adding at the end the following: ‘‘With 
respect to fiscal years beginning with fiscal year 
2017, payment for medical assistance for individuals 
who are eligible for such assistance only on the basis 
of section 1902(a)(10)(A)(ii)(XVIII) shall not be 
taken into account in applying subsection (f) (as in-
creased in accordance with paragraphs (1), (2), (3), 
and (5) of this subsection) to such commonwealth or 
territory for such fiscal year.’’. 
(2) TECHNICAL AMENDMENT.—Such section is 
further amended by striking ‘‘(3), and (4)’’ and in-
serting ‘‘(3), and (5)’’. 
(b) APPLICATION OF ENHANCED FMAP FOR HIGH-
EST STATE.—Section 1905(b) of such Act (42 U.S.C. 
1396d(b)) is amended by adding at the end the following: 
‘‘Notwithstanding the first sentence of this subsection, 
with respect to medical assistance described in clause (4) 
of such sentence that is furnished in Puerto Rico, the 
United States Virgin Islands, Guam, the Commonwealth 
of the Northern Mariana Islands, or American Samoa in 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00450
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
451 
a fiscal year, the Federal medical assistance percentage 
is equal to the highest such percentage applied under such 
clause for such fiscal year for any of the 50 States or the 
District of Columbia that provides such medical assistance 
for any portion of such fiscal year.’’ 
(c) EFFECTIVE DATE.—The amendments made by 
this section shall apply to payment for medical assistance 
for items and services furnished on or after October 1, 
2016. 
SEC. 704. CANCER PREVENTION AND TREATMENT DEM-
ONSTRATION FOR ETHNIC AND RACIAL MI-
NORITIES. 
(a) DEMONSTRATION.— 
(1) IN GENERAL.—The Secretary of Health and 
Human Services (in this section referred to as the 
‘‘Secretary’’) shall conduct demonstration projects 
(in this section referred to as ‘‘demonstration 
projects’’) for the purpose of developing models and 
evaluating methods that— 
(A) improve the quality of items and serv-
ices provided to target individuals in order to 
facilitate reduced disparities in early detection 
and treatment of cancer; 
(B) improve clinical outcomes, satisfaction, 
quality of life, appropriate use of items and 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00451
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
452 
services covered under the Medicare Program 
under title XVIII of the Social Security Act (42 
U.S.C. 1395 et seq.), and referral patterns with 
respect to target individuals with cancer; 
(C) eliminate disparities in the rate of pre-
ventive cancer screening measures, such as Pap 
smears, prostate cancer screenings, colon cancer 
screenings, breast cancer screenings, and com-
puted tomography (CT) scans, for lung cancer 
among target individuals; 
(D) promote collaboration with community- 
based organizations to ensure cultural com-
petency of health care professionals and lin-
guistic access for target individuals who are 
persons with limited-English proficiency; and 
(E) encourage the incorporation of commu-
nity health workers to increase the efficiency 
and appropriateness of cancer screening pro-
grams. 
(2) COMMUNITY HEALTH WORKER DEFINED.— 
In this section, the term ‘‘community health worker’’ 
includes a community health advocate, a lay health 
worker, a community health representative, a peer 
health promotor, a community health outreach work-
er, and a promotore de salud, who promotes health 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00452
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
453 
or nutrition within the community in which the indi-
vidual resides. 
(3) TARGET
INDIVIDUAL
DEFINED.—In this 
section, the term ‘‘target individual’’ means an indi-
vidual of a racial and ethnic minority group, as de-
fined in section 1707(g)(1) of the Public Health 
Service Act (42 U.S.C. 300u–6(g)(1)), who is enti-
tled to benefits under part A, and enrolled under 
part B, of title XVIII of the Social Security Act. 
(b) PROGRAM DESIGN.— 
(1) INITIAL DESIGN.—Not later than 1 year 
after the date of the enactment of this Act, the Sec-
retary shall evaluate best practices in the private 
sector, community programs, and academic research 
of methods that reduce disparities among individuals 
of racial and ethnic minority groups in the preven-
tion and treatment of cancer and shall design the 
demonstration projects based on such evaluation. 
(2) NUMBER AND PROJECT AREAS.—Not later 
than 2 years after the date of the enactment of this 
Act, the Secretary shall implement at least nine 
demonstration projects, including the following: 
(A) Two projects, each of which shall tar-
get different ethnic subpopulations, for each of 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00453
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
454 
the four following major racial and ethnic mi-
nority groups: 
(i) American Indians and Alaska Na-
tives, Eskimos and Aleuts. 
(ii) Asian-Americans. 
(iii) Blacks/African-Americans. 
(iv) Latinos or Hispanics. 
(v) Native Hawaiians and other Pa-
cific Islanders. 
(B) One project within the Pacific Islands 
or United States insular areas. 
(C) At least one project each in a rural 
area and inner-city area. 
(3) EXPANSION
OF
PROJECTS; IMPLEMENTA-
TION
OF
DEMONSTRATION
PROJECT
RESULTS.—If 
the initial report under subsection (c) contains an 
evaluation that demonstration projects— 
(A) reduce expenditures under the Medi-
care Program under title XVIII of the Social 
Security Act (42 U.S.C. 1395 et seq.); or 
(B) do not increase expenditures under the 
Medicare Program and reduce racial and ethnic 
health disparities in the quality of health care 
services provided to target individuals and in-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00454
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
455 
crease satisfaction of Medicare beneficiaries and 
health care providers; 
the Secretary shall continue the existing demonstra-
tion projects and may expand the number of dem-
onstration projects. 
(c) REPORT TO CONGRESS.— 
(1) IN GENERAL.—Not later than 2 years after 
the date the Secretary implements the initial dem-
onstration projects, and biannually thereafter, the 
Secretary shall submit to Congress a report regard-
ing the demonstration projects. 
(2) CONTENTS OF REPORT.—Each report under 
paragraph (1) shall include the following: 
(A) A description of the demonstration 
projects. 
(B) An evaluation of— 
(i) the cost effectiveness of the dem-
onstration projects; 
(ii) the quality of the health care serv-
ices provided to target individuals under 
the demonstration projects; and 
(iii) beneficiary and health care pro-
vider satisfaction under the demonstration 
projects. 
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00455
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
456 
(C) Any other information regarding the 
demonstration projects that the Secretary de-
termines to be appropriate. 
(d) WAIVER AUTHORITY.—The Secretary shall waive 
compliance with the requirements of title XVIII of the So-
cial Security Act (42 U.S.C. 1395 et seq.) to such extent 
and for such period as the Secretary determines is nec-
essary to conduct demonstration projects. 
SEC. 705. REDUCING CANCER DISPARITIES WITHIN MEDI-
CARE. 
(a) DEVELOPMENT OF MEASURES OF DISPARITIES 
IN QUALITY OF CANCER CARE.— 
(1) DEVELOPMENT OF MEASURES.—The Sec-
retary of Health and Human Services (in this sec-
tion referred to as the ‘‘Secretary’’) shall enter into 
an agreement with an entity that specializes in de-
veloping quality measures for cancer care under 
which the entity shall develop a uniform set of meas-
ures to evaluate disparities in the quality of cancer 
care and annually update such set of measures. 
(2) MEASURES TO BE INCLUDED.—Such set of 
measures shall include, with respect to the treatment 
of cancer, measures of patient outcomes, the process 
for delivering medical care related to such treat-
ment, patient counseling and engagement in deci-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00456
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS
457 
sionmaking, patient experience of care, resource use, 
and practice capabilities, such as care coordination. 
(b) ESTABLISHMENT OF REPORTING PROCESS.— 
(1) IN GENERAL.—The Secretary shall establish 
a reporting process that requires and provides for a 
method for health care providers specified under 
paragraph (2) to submit to the Secretary and make 
public data on the performance of such providers 
during each reporting period through use of the 
measures developed pursuant to subsection (a). Such 
data shall be submitted in a form and manner and 
at a time specified by the Secretary. 
(2) SPECIFICATION OF PROVIDERS TO REPORT 
ON
MEASURES.—The Secretary shall specify the 
classes of Medicare providers of services and sup-
pliers, including hospitals, cancer centers, physi-
cians, primary care providers, and specialty pro-
viders, that will be required under such process to 
publicly report on the measures specified under sub-
section (a). 
(3) ASSESSMENT
OF
CHANGES.—Under such 
reporting process, the Secretary shall establish a for-
mat that assesses changes in both the absolute and 
relative disparities in cancer care over time. These 
measures shall be presented in an easily comprehen-
VerDate Sep 11 2014 
08:12 Jun 15, 2016
Jkt 059200
PO 00000
Frm 00457
Fmt 6652
Sfmt 6201
E:\BILLS\H5475.IH
H5475
rmajette on DSK2TPTVN1PROD with BILLS